ANI Pharma Inc Contracts & Agreements

Amendment No. 2024-2 to ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (Filed With SEC on February 29, 2024)

Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc (Filed With SEC on February 29, 2024)

Amendment to Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc (Filed With SEC on February 29, 2024)

Notice of Termination of Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc (Filed With SEC on February 29, 2024)

Form of Indemnification Agreement (Filed With SEC on February 29, 2024)

Agreement of Purchase and Sale between ANI Pharmaceuticals Canada, Inc. and 1540700 Ontario Limited (Filed With SEC on February 23, 2024)

Underwriting Agreement, dated May 11, 2023, by and between ANI Pharmaceuticals, Inc. and Guggenheim Securities, LLC (Filed With SEC on May 12, 2023)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 8, 2022)

Asset Purchase Agreement between Cranford Pharmaceuticals, LLC and ANI Pharmaceuticals, Inc (Filed With SEC on May 10, 2022)

Asset Purchase Agreement between Holmdel Pharmaceuticals, LP and ANI Pharmaceuticals, Inc (Filed With SEC on May 10, 2022)

Certain information has been excluded from this agreement (indicated by [***]) because such information is both not material and the type that the registrant treats as private or... (Filed With SEC on March 15, 2022)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2022)

ANI Pharmaceuticals, Inc. Executive Incentive Bonus Plan (Filed With SEC on February 28, 2022)

Registration Rights Schedule to the Merger Agreement, effective as of November 19, 2021 (Filed With SEC on November 26, 2021)

Underwriting Agreement, dated November 3, 2021, between ANI Pharmaceuticals, Inc. and Guggenheim Securities, LLC (Filed With SEC on November 4, 2021)

Description of Securities (Filed With SEC on March 11, 2021)

Form of Option Agreement (Filed With SEC on March 11, 2021)

Agreement and Plan of Merger dated March 8, 2021 by and among ANI Pharmaceuticals, Inc., Nile Merger Sub LLC, Novitium Pharma LLC, Esjay LLC, Chali Properties, LLC, Chad Gassert,... (Filed With SEC on March 9, 2021)

Support Agreement, dated March 8, 2021 among ANI Pharmaceuticals, Inc., Nile Merger Sub LLC, Novitium Pharma LLC, Esjay Pharma, LLC, Chali Properties, LLC, Chad Gassert, Muthusamy... (Filed With SEC on March 9, 2021)

Equity Commitment and Investment Agreement dated March 8, 2021 by and between ANI Pharmaceuticals, Inc. and Ampersand 2020 Limited Partnership (Filed With SEC on March 9, 2021)

Transition and Separation Agreement dated February 11, 2021 between ANI Pharmaceuticals, Inc. and Robert Schrepfer (Filed With SEC on February 17, 2021)

Inducement Stock Option Award Agreement, effective as of September 8, 2020, between ANI Pharmaceuticals, Inc. and Nikhil Lalwani (Filed With SEC on November 5, 2020)

ANI Pharmaceuticals, Inc. Sixth Amended and Restated 2008 Incentive Plan (Filed With SEC on August 6, 2020)

Employment Agreement between Nikhil Lalwani and ANI Pharmaceuticals, Inc., dated July 24, 2020 (Filed With SEC on August 3, 2020)

Asset Purchase Agreement between Amerigen Pharmaceuticals LTD. and ANI Pharmaceuticals, Inc (Filed With SEC on February 27, 2020)

Form of Restricted Stock Grant Agreement (Filed With SEC on February 27, 2020)

Form of Incentive Option Agreement (Filed With SEC on February 27, 2020)

Form of Non- Statutory Stock Option Agreement (Filed With SEC on February 27, 2020)

Employment Agreement, entered into by the Company and Arthur S. Przybyl (Filed With SEC on January 22, 2020)

Employment Agreement, entered into by the Company and Stephen P. Carey (Filed With SEC on January 22, 2020)

Employment Agreement, entered into by the Company and Robert Schrepfer (Filed With SEC on January 22, 2020)

Employment Agreement, entered into by the Company and James G. Marken (Filed With SEC on January 22, 2020)

Amendment No. 4 to Asset Purchase Agreement between ANI Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc (Filed With SEC on May 9, 2019)

Stock Purchase Agreement by and among WellSpring Pharma Services Inc., WSP Pharma Holdings, LLC, ANI Pharmaceuticals Canada Inc., and ANI Pharmaceuticals, Inc (Filed With SEC on November 6, 2018)

Asset Purchase Agreement between AstraZeneca AB, AstraZeneca UK Limited, and ANI Pharmaceuticals, Inc (Filed With SEC on February 27, 2018)

Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 4, 2017)

ANI PHARMACEUTICALS, INC., ANIP ACQUISITION COMPANY, as Borrowers and ANIP PARTNER, LLC, AP EUROPEAN HOLDINGS, LLC, ANIP CO-OP, LLC, as Guarantors (Filed With SEC on August 4, 2016)

Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 5, 2016)

210 Main Street West, Baudette, MN 56623 Phone ###-###-#### Fax ###-###-#### Toll-Free ###-###-#### (Filed With SEC on April 27, 2016)

SEPARATION AGREEMENT AND RELEASE (Filed With SEC on April 27, 2016)

Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on November 3, 2015)

Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for ConfidentialTreatment under Rule 406 under the Securities... (Filed With SEC on November 3, 2015)

INDENTURE ANI PHARMACEUTICALS, INC. and THE BANK OF NEW YORK MELLON as Trustee (Filed With SEC on December 10, 2014)

ANI PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 10, 2014 3.00% Convertible Senior Notes due 2019 (Filed With SEC on December 10, 2014)

[Signature Pageto Additional Bond Hedge Confirmation] (Filed With SEC on December 10, 2014)

[Signature Page to Additional Warrant Confirmation] (Filed With SEC on December 10, 2014)

3.00% Convertible Senior Notes due 2019 ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT December 4, 2014 (Filed With SEC on December 8, 2014)

[Signature Page to Base Bond Hedge Confirmation] (Filed With SEC on December 8, 2014)

Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities... (Filed With SEC on November 10, 2014)

Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on November 10, 2014)

FORM OF INCENTIVE STOCK OPTION AGREEMENT (Officer) (Filed With SEC on April 4, 2014)

FORM OF NON-STATUTORY STOCK OPTION AGREEMENT (Non-Employee Director) (Filed With SEC on April 4, 2014)

1,402,525 Shares ANI PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 5, 2014)

AMENDMENT NO. 3 TO TRANSACTION BONUS AGREEMENT (Filed With SEC on June 21, 2013)

AMENDMENT NO. 2 TO TRANSACTION BONUS AGREEMENT (Filed With SEC on April 26, 2013)

AMENDMENT NO. 1 TO TRANSACTION BONUS AGREEMENT (Filed With SEC on April 26, 2013)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 26, 2013)

AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among BIOSANTE PHARMACEUTICALS, INC. ANI MERGER SUB, INC. and ANIP ACQUISITION COMPANY Dated as of April 12, 2013 (Filed With SEC on April 12, 2013)

FORM OF AMENDED AND RESTATED VOTING AGREEMENT (Filed With SEC on April 12, 2013)

FORM OF AMENDED AND RESTATED LOCK-UP AGREEMENT (Filed With SEC on April 12, 2013)

SEPARATION AGREEMENT AND RELEASE (Filed With SEC on March 15, 2013)

BIOSANTE PHARMACEUTICALS, INC. DESCRIPTION OF NON-EMPLOYEE DIRECTOR COMPENSATION ARRANGEMENTS (Filed With SEC on February 28, 2013)

AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on December 11, 2012)

Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)

[Logo of ANI Pharmaceuticals] (Filed With SEC on December 11, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on December 11, 2012)

ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENT (Filed With SEC on December 11, 2012)

ANIP ACQUISITION COMPANY As of October 3, 2012 (Filed With SEC on December 11, 2012)

LOAN AND SECURITY AGREEMENT (Filed With SEC on December 11, 2012)

NOTE PURCHASE AGREEMENT (Filed With SEC on December 11, 2012)

DEVELOPMENT AND LICENSE AGREEMENT between TEVA PHARMACEUTICALS USA, INC. 1090 Horsham Road, North Wales, PA 19454 (Teva) and BIOSANTE PHARMACEUTICALS, INC. 111 Barclay Boulevard,... (Filed With SEC on November 8, 2012)

FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (First Amendment) between TEVA PHARMACEUTICALS USA, INC. 1090 Horsham Road, North Wales, PA 19454 (Teva) and BIOSANTE... (Filed With SEC on November 8, 2012)

THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on November 8, 2012)

AGREEMENT AND PLAN OF MERGER by and between BIOSANTE PHARMACEUTICALS, INC. and ANIP ACQUISITION COMPANY Dated as of October 3, 2012 (Filed With SEC on October 4, 2012)

VOTING AGREEMENT (Filed With SEC on October 4, 2012)

FORM OF LOCK-UP AGREEMENT (Filed With SEC on October 4, 2012)

[Remainder of page intentionally left blank] (Filed With SEC on August 17, 2012)

Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC. (Filed With SEC on August 17, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 17, 2012)

BIOSANTE PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN (Amended on May 30, 2012) (Filed With SEC on June 1, 2012)

FORM OF INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on June 1, 2012)

FORM OF NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on June 1, 2012)

BIOSANTE PHARMACEUTICALS, INC. SECURITIES EXCHANGE AGREEMENT FEBRUARY 7, 2012 (Filed With SEC on May 8, 2012)

BIOSANTE PHARMACEUTICALS, INC. SECURITIES EXCHANGE AGREEMENT FEBRUARY 15, 2012 (Filed With SEC on May 8, 2012)

BIOSANTE PHARMACEUTICALS, INC. DESCRIPTION OF NON-EMPLOYEE DIRECTOR COMPENSATION ARRANGEMENTS (Filed With SEC on March 13, 2012)

BIOSANTE PHARMACEUTICALS, INC. OFFICER SEVERANCE POLICY (Filed With SEC on August 5, 2011)

16,000,000 Shares BioSante Pharmaceuticals, Inc. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENT (Filed With SEC on July 28, 2011)

BIOSANTE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN (As Amended on May 26, 2011) (Filed With SEC on May 27, 2011)

FORM OF INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on May 27, 2011)

FORM OF NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on May 27, 2011)

BIOSANTE PHARMACEUTICALS, INC. PERFORMANCE INCENTIVE PLAN (Filed With SEC on May 27, 2011)

CHANGE OF CONTROL AND SEVERANCE AGREEMENT (Filed With SEC on March 16, 2011)

BIOSANTE PHARMACEUTICALS, INC. DESCRIPTION OF NON-EMPLOYEE DIRECTOR COMPENSATION ARRANGEMENTS (Filed With SEC on March 16, 2011)

LICENSE AGREEMENT between PERMATEC TECHNOLOGIE, AG and BIOSANTE PHARMACEUTICALS, INC. [Portions of this Exhibit have been omitted pursuant to a request for confidentiality under... (Filed With SEC on March 16, 2011)

Amendment No. 1 to the License Agreement dated 13thof June 2000 (the Agreement) by and between Antares Pharma IPL AG, Zug, Switzerland as Licensor (formerly known as Permatec... (Filed With SEC on March 16, 2011)

AMENDMENT NO. 3 to the License Agreement dated 13thof June, 2000 (the Agreement) by and between ANTARES Pharma IPL AG, Zug, Baarerstrasse 95, 6301 Zug, Switzerland as Licensor... (Filed With SEC on March 16, 2011)

Amendment No. 4 to the License Agreement dated 13thof June 2000 (the Agreement) by and between Antares Pharma IPL AG, Zug, Switzerland as Licensor (formerly known as Permatec... (Filed With SEC on March 16, 2011)

Amendment No. 5 to the License Agreement dated 13thof June 2000 (the Agreement) by and between Antares Pharma IPL AG Zug, Switzerland as Licensor (formerly known as Permatec... (Filed With SEC on March 16, 2011)

Amendment No. 6 to the License Agreement dated 13th of June 2000 by and between Antares Pharma IPL AG, Zug, Switzerland as Licensor (formerly known as Permatec Technologies AG)... (Filed With SEC on March 16, 2011)

[Remainder of page intentionally left blank] (Filed With SEC on March 4, 2011)

Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC. (Filed With SEC on March 4, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 4, 2011)

NINTH AMENDMENT TO LEASE (Filed With SEC on January 27, 2011)

BIOSANTE PHARMACEUTICALS, INC. WARRANT (Filed With SEC on November 9, 2009)

BIOSANTE PHARMACEUTICALS, INC., and U.S. BANK NATIONAL ASSOCIATION, Trustee SUPPLEMENTAL INDENTURE Dated as of October 14, 2009 To INDENTURE Dated as of October 20, 2004 Relating... (Filed With SEC on October 14, 2009)

BIOSANTE PHARMACEUTICALS, INC., and U.S. BANK NATIONAL ASSOCIATION, Trustee SUPPLEMENTAL INDENTURE Dated as of October 14, 2009 To INDENTURE Dated as of June 24, 2009 Relating to... (Filed With SEC on October 14, 2009)

[Remainder of page intentionally left blank] (Filed With SEC on August 14, 2009)

Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC. (Filed With SEC on August 14, 2009)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 14, 2009)

[BIOSANTE LETTERHEAD] (Filed With SEC on August 7, 2009)

AGREEMENT AND PLANOF MERGER between BIOSANTEPHARMACEUTICALS, INC. and CELL GENESYS, INC. Dated as of June 29,2009 (Filed With SEC on June 30, 2009)

VOTING AGREEMENT (Filed With SEC on June 30, 2009)

FORM OFVOTING AGREEMENT (Filed With SEC on June 30, 2009)

BIOSANTEPHARMACEUTICALS, INC. DESCRIPTIONOF NON-EMPLOYEE DIRECTOR COMPENSATIONARRANGEMENTS (Filed With SEC on March 16, 2009)

WARRANT (Filed With SEC on December 18, 2008)

COMMONSTOCK PURCHASE AGREEMENT byand between KINGSBRIDGECAPITAL LIMITED and BIOSANTEPHARMACEUTICALS INC. datedas of December 15, 2008 (Filed With SEC on December 18, 2008)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on December 18, 2008)

TERMINATION, RELEASE ANDSETTLEMENT AGREEMENT (Filed With SEC on August 11, 2008)

AMENDEDAND RESTATED EMPLOYMENT LETTER AGREEMENT (Filed With SEC on July 18, 2008)

BIOSANTEPHARMACEUTICALS, INC. 2008STOCK INCENTIVE PLAN (Filed With SEC on June 13, 2008)

FORMOF INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on June 13, 2008)

FORMOF NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on June 13, 2008)

FORMOF NON-STATUTORY STOCK OPTION AGREEMENT (Non-EmployeeDirector) (Filed With SEC on June 13, 2008)

SIXTHAMENDMENT TO LEASE (Filed With SEC on April 21, 2008)

LibiGel once daily transdermal testosterone gel in Phase III development for treatment of female sexual dysfunction (FSD) (Filed With SEC on March 17, 2008)

FIFTH AMENDMENT TO LEASE (Filed With SEC on November 6, 2007)

BIOSANTE PHARMACEUTICALS, INC. WARRANT (Filed With SEC on June 14, 2007)

SUBSCRIPTION AGREEMENT (Filed With SEC on May 25, 2007)

BIOSANTE PHARMACEUTICALS, INC. WARRANT (Filed With SEC on May 25, 2007)

Employment Agreement, dated January 21, 1998, between BioSante Pharmaceuticals, Inc. and Stephen M. Simes, as amended (Filed With SEC on March 27, 2007)

Third Amendment to Lease dated as of August 14, 2006, by and between BioSante Pharmaceuticals, Inc. and Highlands Park Associates (Filed With SEC on March 27, 2007)

Amendment No. 6 to the License Agreement, dated October 20, 2006 between Antares Pharma IPL AG and BioSante Pharmaceuticals, Inc (Filed With SEC on March 27, 2007)

Exclusive Sublicense Agreement dated as of November 7, 2006 between BioSante and Bradley Pharmaceuticals, Inc (Filed With SEC on March 27, 2007)

Description of Non-Employee Director Compensation Arrangements (Filed With SEC on March 27, 2007)

Description of Executive Officer Compensation Arrangements (Filed With SEC on March 27, 2007)

Fourth Amendment to Lease dated as of March 7, 2007, by and between BioSante Pharmaceuticals, Inc. and LaSalle Bank National Association, as successor trustee to American National... (Filed With SEC on March 7, 2007)

Fourth Amendment to Exclusive License Agreement Agreement Control No. 1997-04-0671 for Selected Applications of Coated Nanocrystalline Particles between The Regents of the... (Filed With SEC on November 14, 2006)

CONFIDENTIAL SETTLEMENT AGREEMENT (Filed With SEC on August 14, 2006)

BIOSANTE PHARMACEUTICALS, INC. WARRANT (Filed With SEC on July 24, 2006)

SUBSCRIPTION AGREEMENT (Filed With SEC on July 10, 2006)

BIOSANTE PHARMACEUTICALS, INC. WARRANT (Filed With SEC on July 10, 2006)

BIOSANTE PHARMACEUTICALS, INC. AMENDED AND RESTATED 1998 STOCK PLAN (As amended through June 6, 2006) (Filed With SEC on June 12, 2006)

BIOSANTE PHARMACEUTICALS, INC. DESCRIPTION OF NON-EMPLOYEE DIRECTOR COMPENSATION ARRANGEMENTS (Filed With SEC on March 31, 2006)

BIOSANTE PHARMACEUTICALS, INC. DESCRIPTION OF EXECUTIVE OFFICER COMPENSATION ARRANGEMENTS (Filed With SEC on March 31, 2006)

THIRD AMENDMENT TO LEASE (Filed With SEC on February 1, 2006)

SECOND AMENDMENT TO LEASE (Filed With SEC on January 6, 2005)

SECOND AMENDMENT TO LEASE (Filed With SEC on September 1, 2004)

COMMON STOCK AND WARRANT PURCHASE AGREEMENT by and among BioSantePharmaceuticals, Inc. and the partiesnamed herein on Schedule 1, as Purchasers August 4, 2003 (Filed With SEC on August 6, 2003)

FORM OF COMMON STOCK PURCHASE WARRANT To Purchase Shares Shares of Common Stock of BIOSANTE PHARMACEUTICALS, INC. (Filed With SEC on August 6, 2003)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on August 6, 2003)

Category

Industry

Companies

Contracts

ANI Pharma Inc Contracts & Agreements